CRL · Charles River Laboratories International, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $743.07M | $751.00M | $747.86M | $665.10M | $619.92M | $528.93M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $403.31M | $361.74M | $314.12M | $303.87M | $265.54M | $234.92M |
| Operating Income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M | $432.73M |
| Interest Expense | $107.03M | $59.29M | $136.71M | $59.29M | $73.91M | $86.43M |
| Income Tax | $42.66M | $67.82M | $100.91M | $130.38M | $81.87M | $81.81M |
| Net Income | ($144.34M) | $22.20M | $474.62M | $486.23M | $390.98M | $364.30M |
| EPS - Basic | ($2.91) | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 |
| EPS - Diluted | ($2.91) | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $213.77M | $194.61M | $276.77M | $233.91M | $241.21M | $228.42M |
| Accounts Receivable | $708.86M | $720.91M | $780.38M | $752.39M | $642.88M | $617.74M |
| Inventory | $299.10M | $278.54M | $380.26M | $255.81M | $199.15M | $185.69M |
| Accounts Payable | $148.80M | $140.34M | $168.94M | $205.91M | $198.13M | $122.47M |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B |
| Current Liabilities | $1.12B | $994.10M | $1.06B | $1.09B | $1.03B | $839.75M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $980.75M | $625.41M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $737.65M | $734.58M | $683.90M | $619.64M | $480.94M | $546.58M |
| Investing Cash Flow | ($209.32M) | ($245.09M) | ($563.15M) | ($607.92M) | ($1.44B) | ($601.54M) |
| Financing Cash Flow | ($536.73M) | ($550.93M) | ($85.52M) | ($42.40M) | $672.60M | $47.25M |
| CapEx | $219.15M | $232.97M | $318.53M | $324.73M | $228.77M | $166.56M |
| Free Cash Flow | $518.49M | $501.61M | $365.37M | $294.91M | $252.16M | $380.01M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% |
| EBITDA margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% |
| Net margin | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% |
| Free cash flow margin | 12.9% | 12.4% | 8.8% | 7.4% | 7.1% | 13.0% |
| FCF / Net income | -3.59 | 22.59 | 0.77 | 0.61 | 0.64 | 1.04 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 18.5% | 18.5% | 18.1% | 16.7% | 17.5% | 18.1% |
| Effective tax rate | - | 75.3% | 17.5% | 21.1% | 17.3% | 18.3% |
| Return on assets | -2.0% | 0.3% | 5.8% | 6.4% | 5.6% | 6.6% |
| Return on equity | -4.6% | 0.6% | 13.2% | 16.3% | 15.4% | 17.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 |
| Quick ratio | 1.02 | 1.13 | 1.16 | 1.08 | 1.04 | 1.21 |
| Cash ratio | 0.19 | 0.20 | 0.26 | 0.21 | 0.23 | 0.27 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 0.2x | 3.8x | 4.5x | 11.0x | 8.0x | 5.0x |
| Equity multiplier | 2.25 | 2.17 | 2.28 | 2.55 | 2.77 | 2.60 |
| Liabilities / Assets | 0.55 | 0.53 | 0.55 | 0.60 | 0.63 | 0.61 |
| Efficiency | ||||||
| Asset turnover | 0.56 | 0.54 | 0.50 | 0.52 | 0.50 | 0.53 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 64d | 65d | 69d | 69d | 66d | 77d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 923.0x | 25.6x | 23.0x | 49.6x | 35.0x |
| P / B | 3.1x | 2.8x | 3.4x | 3.8x | 7.6x | 6.0x |
| P / S | 2.5x | 2.4x | 2.9x | 2.8x | 5.5x | 4.4x |
| EV / EBITDA | 22.6x | 15.8x | 12.8x | 11.5x | 22.4x | 18.7x |
| Growth | ||||||
| Revenue growth (YoY) | -0.9% | -1.9% | 3.9% | 12.3% | 21.1% | 11.5% |
| Revenue CAGR (3y) | 0.3% | 4.6% | 12.2% | 14.9% | 28.2% | 16.3% |
| Revenue CAGR (5y) | 6.5% | 9.1% | 19.7% | 16.4% | 16.1% | 16.5% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -88.9% | -63.2% | -5.2% | 10.4% | 36.3% | 23.2% |
| Net income growth (YoY) | - | -95.3% | -2.4% | 24.4% | 7.3% | 44.6% |
| EPS growth (YoY) | - | -97.8% | -2.7% | 24.7% | 5.6% | 42.0% |
| EPS CAGR (3y) | - | -70.3% | 8.6% | 23.2% | 18.0% | 41.5% |
| EPS CAGR (5y) | - | -47.6% | 14.8% | 30.1% | 18.7% | 18.1% |
| FCF growth (YoY) | 3.4% | 37.3% | 23.9% | 17.0% | -33.6% | 26.4% |
| FCF CAGR (5y) | 6.4% | 10.8% | 15.6% | 4.6% | 0.6% | 11.1% |
| Book value growth (YoY) | -8.6% | -3.8% | 20.9% | 17.4% | 19.9% | 29.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-27.
Business segments
$3.17B totalDiscovery And Safety Assessment Segment$2.40B · 75.6%
Research Models And Services Segment$389.09M · 12.3%
Manufacturing Support Segment$383.68M · 12.1%
Product / service
$4.02B totalService$3.25B · 80.9%
Product$765.28M · 19.1%
Geographic
$4.02B totalUS$2.14B · 53.3%
Europe$1.10B · 27.5%
CA$501.02M · 12.5%
Asia Pacific$205.02M · 5.1%
Other$64.86M · 1.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.11
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing CHARLES RIVER LABORATORIES INTERNATIONAL against the 5 most active filers in the same SIC group.